Investment analysts at BTIG Research assumed coverage on shares of OrthoPediatrics Corp. (NASDAQ:KIDS) in a research note issued to investors on Monday. The brokerage set a “buy” rating and a $24.00 price target on the stock. BTIG Research’s target price would indicate a potential upside of 15.38% from the stock’s current price.
Separately, Piper Jaffray Companies began coverage on OrthoPediatrics Corp. in a research note on Monday. They issued an “overweight” rating for the company.
OrthoPediatrics Corp. (KIDS) opened at $20.80 on Monday. OrthoPediatrics Corp. has a 1-year low of $17.03 and a 1-year high of $21.00.
COPYRIGHT VIOLATION WARNING: This story was first reported by Community Financial News and is the property of of Community Financial News. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this story can be viewed at https://www.com-unik.info/2017/11/06/orthopediatrics-corp-kids-coverage-initiated-at-btig-research.html.
In other OrthoPediatrics Corp. news, Director Harold Ruf bought 11,500 shares of the company’s stock in a transaction that occurred on Monday, October 16th. The stock was purchased at an average cost of $13.00 per share, for a total transaction of $149,500.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
OrthoPediatrics Corp. Company Profile
OrthoPediatrics Corp. is a medical device company. The Company designs, develops and commercializes orthopedic implants and instruments to meet the specialized needs of pediatric surgeons and their patients. It operates through the OrthoPediatrics segment, which designs, develops and markets implants and devices for children with orthopedic problems.
What are top analysts saying about OrthoPediatrics Corp.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for OrthoPediatrics Corp. and related companies.